



ROS1 Positive Lung Cancer: Managing Resistance and Advancing Research


Show Notes

In this Hope With Answers episode, host Diane Mulligan interviews Dr. Tejas Patil, an oncologist specializing in lung cancer, about ROS1-positive lung cancer. As Dr. Patil explains, "ROS1 is a type of mutation that we see in patients who have lung cancer. It's one of many but it's an important one because there is targeted treatments available to these patients that really are not like chemotherapy."

A ROS1-positive lung cancer, also known as a ROS1 rearrangement in lung cancer, refers to any lung cancer that tests positive for a fusion in the ROS1 gene. ROS1 rearrangements occur in approximately 1-2% of non-small cell lung cancer (NSCLC) patients. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.

Guests:

Tejas Patil, MD / Assistant Professor, Medicine-Medical Oncology, University of Colorado Anschutz Medical Campus



Resources:

[What is ROS1-positive in lung cancer and how is it treated? | LCFA](#)
[ROS1-Positive Lung Cancer: Symptoms, Treatment, and More](#)

Lysa Buonanno, Lung Cancer survivor, a mother of two, who has ROS1 mutation and is being treated with the targeted therapy Xalkori.



Resources:

[Lysa Buonanno | LCFA Speakers Bureau](#)
[Survivor Finds Strength in Relationships](#)

LCFA's mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

While raising funds to support lung cancer research, LCFA will raise the public's awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.

You can also join the conversation with LCFA on [Facebook](#), [Twitter](#), and [Instagram](#).